V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation
11.6.2024 11:00:00 EEST | Business Wire | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/
V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia.
V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video industry, such as MPEG-5 LCEVC and VC-6. It has also developed V-Nova PresenZ, a unique volumetric format that enables cinematic 6 Degrees of Freedom (6DoF) immersive experiences for the first time. Recently, V-Nova has demonstrated how its technologies drive substantial efficiencies and unique use cases in AI media indexing, multimodal Generative AI, and Intelligent Edge applications.
V-Nova’s extensive patent portfolio supports a variety of industries, including Entertainment, Social Media, Streaming, Broadcasting, Cloud Gaming, Virtual and Augmented Reality, Industrial Applications, Automotive, Security, and Defence.
“This milestone in V-Nova’s technology portfolio represents a systemic achievement tied to our company structure, strategic focus, and the highly talented individuals we have brought together,” said Guido Meardi, CEO at V-Nova.
Continuous research and development are a cornerstone of V-Nova’s technology roadmap and its resource allocation. The company has been granted 200 patents in the past 12 months alone, with 9 UK patents granted in under 200 days since the filing date. This rapid pace of innovation highlights the quality of its applications and the dedication of its team.
“V-Nova’s success is a result of its company culture, which supports diversity of opinions and encourages collaboration,” said Stergios Poularakis, Head of Advanced R&D at V-Nova. “Our team brings the right people together to interact, innovate, and create something new and exciting.”
V-Nova’s core IP development includes multi-layer and parallel data coding technology that underpins MPEG-5 LCEVC and VC-6. MPEG-5 LCEVC enables users to implement a new data layer onto an existing codec, improving visual quality, reducing energy consumption during the transcoding process, and enhancing compression efficiency. V-Nova’s innovative approach has recently unlocked new virtual reality and mixed reality use cases. The V-Nova PresenZ format enables photo-realistic immersive experiences at scale, with 6 Degrees of Freedom (6DofF) to allow viewers to ‘step inside’ cinematic content. V-Nova technologies also facilitate AI Media Indexing, Machine Vision, and Large Multimodal Models (LMMs) to interact with data like humans, efficiently processing only the necessary resolution and regions of interest while maintaining the entire signal at maximum quality in efficiently compressed form.
V-Nova continues to invest in innovative research and development. Richard Fish, Patent Attorney at V-Nova commented, “Almost 40% of employees at V-Nova are named as inventors on a patent application, making us one of the most innovative companies in the UK, if not the world.”
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, including MPEG-5 LCEVC and VC-6, are based on the innovative use of AI and parallel processing, improve data, video, imaging, and point-cloud compression, and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 1000 international patents, along with a range of software products and solutions. More about V-Nova: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611724561/en/
Contact information
V-Nova Marketing and Communications:
Joao Felix – press@v-nova.com
Bubble Agency - UK & EMEA Account Director:
Danielle Harper – danielleh@bubbleagency.com
Bubble Agency - Head of Americas:
Kim Willsher – Kimw@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 09:00:00 EEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 06:49:00 EEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom